94 related articles for article (PubMed ID: 25907407)
1. Evaluation of the effect of food and gastric pH on the single-dose pharmacokinetics of cabozantinib in healthy adult subjects.
Nguyen L; Holland J; Mamelok R; Laberge MK; Grenier J; Swearingen D; Armas D; Lacy S
J Clin Pharmacol; 2015 Nov; 55(11):1293-302. PubMed ID: 25907407
[TBL] [Abstract][Full Text] [Related]
2. Influence of Cow's Milk and Esomeprazole on the Absorption of Erlotinib: A Randomized, Crossover Pharmacokinetic Study in Lung Cancer Patients.
Veerman GDM; Hussaarts KGAM; Peric R; Oomen-de Hoop E; Landa KD; van der Leest CH; Broerse SD; Rutten HB; Belderbos HNA; Steendam CMJ; Paats MS; Koolen SLW; Dingemans AC; van Gelder T; van Leeuwen RWF; Aerts JGJV; Mathijssen RHJ
Clin Pharmacokinet; 2021 Jan; 60(1):69-77. PubMed ID: 32557346
[TBL] [Abstract][Full Text] [Related]
3. Sodium citrate buffer improves pazopanib solubility and absorption in gastric acid-suppressed rat model.
Muhammad HJ; Shimada T; Fujita A; Sai Y
Drug Metab Pharmacokinet; 2024 Apr; 55():100995. PubMed ID: 38447327
[TBL] [Abstract][Full Text] [Related]
4. Effect of Food on the Pharmacokinetics and Pharmacodynamics of a Novel Dual Delayed-Release Formulation of Esomeprazole in Healthy Subjects.
Hwang S; Hong SH; Jung J; Chung JY; Jang IJ; Lee S
Clin Pharmacol Drug Dev; 2023 Aug; 12(8):839-844. PubMed ID: 36929154
[TBL] [Abstract][Full Text] [Related]
5. Cabozantinib-induced heart failure.
Sekmek S; Bayram D; Ucar G; Civelek B; Kos FT; Uncu D
J Oncol Pharm Pract; 2024 Jan; 30(1):225-227. PubMed ID: 37817663
[TBL] [Abstract][Full Text] [Related]
6. Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics.
Lu T; Fraczkiewicz G; Salphati L; Budha N; Dalziel G; Smelick GS; Morrissey KM; Davis JD; Jin JY; Ware JA
CPT Pharmacometrics Syst Pharmacol; 2017 Nov; 6(11):747-755. PubMed ID: 28748626
[TBL] [Abstract][Full Text] [Related]
7. Unique Cabozantinib Dosing Considerations in People Living with HIV and Cancer.
Eisenmann ED; Sparreboom A
Clin Cancer Res; 2023 Dec; 29(24):4999-5001. PubMed ID: 37792442
[TBL] [Abstract][Full Text] [Related]
8. Acquired perforating dermatoses and cabozantinib: A novel cutaneous toxicity.
Soto-García D; Suh-Oh HJ; Álvarez C; Martínez-Fernández S; García-Arroyo FR; Couselo-Rodríguez C; Flórez Á
J Dtsch Dermatol Ges; 2024 Apr; 22(4):594-596. PubMed ID: 38426664
[No Abstract] [Full Text] [Related]
9. Cabozantinib for the treatment of metastatic medullary thyroid carcinoma.
Nix NM; Braun K
J Adv Pract Oncol; 2014 Jan; 5(1):47-50. PubMed ID: 25032033
[No Abstract] [Full Text] [Related]
10. Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites.
Lacy S; Hsu B; Miles D; Aftab D; Wang R; Nguyen L
Drug Metab Dispos; 2015 Aug; 43(8):1190-207. PubMed ID: 26015560
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.
Singh RP; Patel B; Kallender H; Ottesen LH; Adams LM; Cox DS
J Clin Pharmacol; 2015 Oct; 55(10):1184-92. PubMed ID: 25998042
[TBL] [Abstract][Full Text] [Related]
12. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review.
Qi XS; Guo XZ; Han GH; Li HY; Chen J
World J Gastroenterol; 2015 May; 21(18):5445-53. PubMed ID: 25987766
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Unexplained Chronic Cough: CHEST Guideline and Expert Panel Report.
Gibson P; Wang G; McGarvey L; Vertigan AE; Altman KW; Birring SS;
Chest; 2016 Jan; 149(1):27-44. PubMed ID: 26426314
[TBL] [Abstract][Full Text] [Related]
14. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
[TBL] [Abstract][Full Text] [Related]
15. Activating MET kinase rearrangements in melanoma and Spitz tumours.
Yeh I; Botton T; Talevich E; Shain AH; Sparatta AJ; de la Fouchardiere A; Mully TW; North JP; Garrido MC; Gagnon A; Vemula SS; McCalmont TH; LeBoit PE; Bastian BC
Nat Commun; 2015 May; 6():7174. PubMed ID: 26013381
[TBL] [Abstract][Full Text] [Related]
16. Immune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapy.
Kwilas AR; Donahue RN; Tsang KY; Hodge JW
Cancer Cell Microenviron; 2015; 2(1):. PubMed ID: 26005708
[TBL] [Abstract][Full Text] [Related]
17. Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen.
Lacin S; Esin E; Karakas Y; Yalcin S
Onco Targets Ther; 2015; 8():1039-42. PubMed ID: 25999738
[TBL] [Abstract][Full Text] [Related]
18. Drug-drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data.
Natale JJ; Spinelli T; Calcagnile S; Lanzarotti C; Rossi G; Cox D; Kashef K
J Oncol Pharm Pract; 2016 Jun; 22(3):485-95. PubMed ID: 25998320
[TBL] [Abstract][Full Text] [Related]
19. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paik PK; Drilon A; Fan PD; Yu H; Rekhtman N; Ginsberg MS; Borsu L; Schultz N; Berger MF; Rudin CM; Ladanyi M
Cancer Discov; 2015 Aug; 5(8):842-9. PubMed ID: 25971939
[TBL] [Abstract][Full Text] [Related]
20. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
